Physician profile
Mark Dammert
NPI 1417168345
$32,835.84
in general payments reported to CMS, 2019-2025
17 companies · $844 in 2025
The $844 reported for 2025 was more than what 76% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $785 · 2021: $20K · 2022: $5,463 · 2023: $4,729 · 2024: $502 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,300 · Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,300.00 |
| Food and Beverage | $1,774.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $29,756.54 | 2019-2025 | |
| Inspire Medical Systems, INC. | $448.21 | 2022-2025 | Inspire |
| Medtronic, INC. | $419.77 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $395.07 | 2021-2025 | Dupixent |
| Genzyme Corporation | $307.08 | 2021-2025 | |
| Acclarent, INC | $293.42 | 2019-2023 | Trudi Nav Cable |
| Olympus America INC. | $278.58 | 2019-2023 | Rhino-Laryngo Videoscope |
| Stryker Corporation | $208.30 | 2019-2021 | |
| Glaxosmithkline, LLC. | $206.92 | 2022-2025 | Nucala |
| Smith+Nephew, INC. | $147.42 | 2019-2023 | Tula, Halo |
| Optinose US, INC. | $93.47 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $86.52 | 2025 | Neffy |
| Intersect Ent, INC. | $73.70 | 2020 | |
| Advanced Bionics, LLC | $60.84 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $22.33 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $19.31 | 2025 | Ryaltris |
| Itamar Medical INC | $18.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dammert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.